DWTX · Dogwood Therapeutics, Inc. · Executive Compensation
$1.15
-0.06 (-4.96%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, there is substantial doubt about the Company's ability to operate as a going concern within one year after the issuance date of these condensed consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$39.09M
Shares
33.99M
Volume · Oct 20
50.35K
Avg daily vol (3M)
69.14K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Greg Duncan | Chairman and Chief Executive Officer | $3,344,728 |
| R. Michael Gendreau | MD, PhD Chief Medical Officer | $1,330,277 |
| Angela Walsh | Chief Financial Officer | $1,252,051 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Greg Duncan | Chairman and Chief Executive Officer | $881,220 |
| R. Michael Gendreau | MD, PhD Chief Medical Officer | $511,616 |
| Angela Walsh | Chief Financial Officer | $364,328 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Greg Duncan | Chairman and Chief Executive Officer | $566,923 |
| R. Michael Gendreau | MD, PhD Chief Medical Officer | $364,942 |
| Angela Walsh | Chief Financial Officer | $282,639 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Greg Duncan | Chairman and Chief Executive Officer | $936,832 |
| R. Michael Gendreau | MD, PhD Chief Medical Officer | $566,176 |
| Angela Walsh | Senior Vice President of Finance | $426,816 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Greg Duncan | Chairman and Chief Executive Officer | $1,099,338 |
| R. Michael Gendreau | MD, PhD Chief Medical Officer | $688,313 |
| Angela Walsh | Senior Vice President of Finance | $413,802 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Greg Duncan | Chief Executive Officer | $3,541,794 |
| Richard Burch | President | $2,655,256 |
| William L. Pridgen | Founder and Chief Executive Officer | $2,424,380 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| William L. Pridgen | Founder and Chief Executive Officer | $350,000 |
| Richard Burch | President | $350,000 |
| Angela Walsh | Vice President of Finance | — |
| Greg Duncan | Chief Executive Officer | — |
| Ralph Grosswald | Vice President of Operations | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Richard J. Whitley, M.D. | director | Appointed | 2025-06-24 |
| Alan Yu | director | Appointed | 2025-06-24 |
| John C. Thomas, Jr. | director | Appointed | 2025-06-24 |
| Melvin Toh, M.B.B.S. | director | Appointed | 2025-06-24 |
| David Keefer | director | Appointed | 2025-06-24 |
| Greg Duncan | director | Appointed | 2025-06-24 |
| Abel De La Rosa, Ph.D. | director | Appointed | 2025-06-24 |
| Angela Walsh | Chief Financial Officer | Appointed | 2024-10-07 |
| Melvin Toh | director of the Company | Appointed | 2024-10-07 |
| Alan Yu | director of the Company | Appointed | 2024-10-07 |
| Richard Burch | Board | Resigned | 2024-10-07 |
Leadership
- Greg Duncan CEO, Board Member
- William L. Pridgen CEO
- Angela Walsh CFO
- Abel De La Rosa, Ph.D. Board Member
- Alan Yu Board Member
- David Keefer Board Member
- John C. Thomas, Jr. Board Member
- Melvin Toh Board Member
- Melvin Toh, M.B.B.S. Board Member
- Richard J. Whitley, M.D. Board Member
- William L. Pridgen, M.D. Board Member